Greater than 32,000 other folks were hospitalized with dengue fever in Bangladesh to this point in 2022. FILE PHOTO: REUTERS


Greater than 32,000 other folks were hospitalized with dengue fever in Bangladesh to this point in 2022. FILE PHOTO: REUTERS

The federal government’s battle towards the scourge of ever-increasing dengue fever infections has confirmed futile.

The collection of annual dengue fever instances has greater just about 20-fold over the last twenty years. Information from the Well being Directorate displays that instances have greater via as much as one lakh in line with yr.

For the entire newest information, apply the Day-to-day Megastar’s Google Information channel.

A brand new dengue vaccine displays promise on this atmosphere, mavens mentioned, however with caveats.

The brand new vaccine, referred to as Qdenga, was once advanced via Eastern corporate Takeda Prescribed drugs Ltd.

The vaccine is in line with a dengue pressure referred to as serotype 2, with elements from 3 different lines connected. The inoculation contains two injections, acceptable to other folks 4 years and older.

The vaccine’s first trial came about within the Dominican Republic, Panama and the Philippines in 1,800 other folks, and the drug is assumed to have produced an immune reaction towards no longer simply serotype 2 however all 4 variants.

The vaccine supplied immunity for 4 years, found out within the first segment trial.

In a 2nd segment trial, greater than 20,000 individuals from Asia and Latin The usa won the vaccine and vaccination was once discovered to cut back hospitalizations via 84% and save you dengue fever in 61%. No safety dangers had been seen.

Talking at a systematic consultation at the sidelines of the 20th World Congress on Tropical Drugs and Malaria in Bangkok, Thailand on October 26 this yr, Takeda researchers mentioned they had been having a look at total efficacy.

Professionals have instructed the federal government believe engaging in a security, efficacy and acceptability trial of the vaccine, which has been authorized in Indonesia and won sure evaluations from a Eu Union advisory staff.

“As we’ve got no longer been a success in controlling the mosquitoes, vaccination could also be an possibility. However there’s a want for a box trial to inspect the protection, efficacy and acceptability of this vaccine towards the dengue. [Qdenga]“, Dr Benazir Ahmed, former member of the Nationwide Immunization Technical Advisory Staff (NITAG) of the Ministry of Well being instructed the Day-to-day Megastar the day prior to this (Thursday).

Professionals, then again, are nonetheless skeptical that the vaccine will probably be similarly efficient towards all 4 lines.

“As a pharmaceutical corporate, they [Takeda] have discovered that their vaccine works smartly in some instances. However there also are issues. Within the Philippines, youngsters vaccinated towards dengue fever [Sanofi’s Dengvaxia] advanced a extra critical situation afterwards,” Professor MA Faiz, former Director Basic of Well being Products and services at DGHS, who attended the convention, instructed this newspaper.

In 2015, Sanofi Pasteur presented the primary dengue vaccine. However the vaccine misplaced its enchantment because it quickly turned into obvious that it was once most effective appropriate for individuals who had already been inflamed with dengue fever.

Licensed via the US-FDA, this vaccine can now most effective be given to youngsters and children nine to 16 years outdated with a prior laboratory-confirmed dengue virus an infection and residing in a space the place dengue is endemic, in line with the Middle for Illness Keep watch over and Prevention.

“[So]we can’t use it till impartial our bodies like GAVI, the Global Well being Group or Unicef ​​suggest it,” mentioned Professor MA Faiz.

On the other hand, he felt that it was once now vital to speak about this vaccine. “If the vaccine is really useful, we need to use it… our respective technical committee can talk about other sides of vaccine doable.

“We’ve already been knowledgeable of this. We will be able to now cross in the course of the learn about document and talk about it with my staff. [NITAG]“, Professor Khan Abul Kalam Azad, head of NITAG, instructed the Day-to-day Megastar.

In regards to the box trial within the nation, he mentioned, “If Bangladesh can take part within the trial, we can know whether or not the vaccine works in our nation or no longer. However we aren’t announcing we are taken with Takeda’s vaccine. till the learn about is done in Indonesia and authorized via the [US]-FDA.”


Leave a Reply

Your email address will not be published. Required fields are marked *